TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

The present invention relates to certain (1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also p...

Full description

Saved in:
Bibliographic Details
Main Authors KAWASAKI, ANDREW, M, LOPEZ, LUIS, A, ULLMAN, BRETT, BUZARD, DANIEL, J, MOODY, JEANNE, V, JONES, ROBERT, M, THORESEN, LARS
Format Patent
LanguageEnglish
French
Published 25.06.2009
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to certain (1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases. La présente invention porte sur certains dérivés d'acide (1,2,4-oxadiazol-3-yl)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-ylcarboxylique de formule (Ia) et sur des sels pharmaceutiquement acceptables de ceux-ci, qui présentent des propriétés pharmacologiques utiles, par exemple, comme agonistes du récepteur S1P1. L'invention porte également sur des compositions pharmaceutiques contenant les composés de l'invention et sur des procédés d'utilisation des composés et compositions de l'invention dans le traitement de troubles associés à S1P1, par exemple le psoriasis, la polyarthrite rhumatoïde, la maladie de Crohn, un rejet de greffe, la sclérose en plaque, le lupus érythémateux disséminé, la rectocolite hémorragique, le diabète de type I, l'acné, les infections ou maladies microbiennes et les infections ou maladies virales.
Bibliography:Application Number: WO2008US13753